@article{RN112,
   author = {Markus, A. F. and Rijnbeek, P. R. and Kors, J. A. and Burn, E. and Duarte-Salles, T. and Haug, M. and Kim, C. and Kolde, R. and Lee, Y. and Park, H. S. and Park, R. W. and Prieto-Alhambra, D. and Reyes, C. and Krishnan, J. A. and Brusselle, G. G. and Verhamme, K. M.},
   title = {Real-world treatment trajectories of adults with newly diagnosed asthma or COPD},
   journal = {BMJ Open Respir Res},
   volume = {11},
   number = {1},
   note = {2052-4439 Markus, Aniek F Orcid: 0000-0001-5779-4794 Rijnbeek, Peter R Orcid: 0000-0003-0621-1979 Kors, Jan A Burn, Edward Orcid: 0000-0002-9286-1128 Duarte-Salles, Talita Orcid: 0000-0002-8274-0357 Haug, Markus Orcid: 0000-0003-0935-3307 Kim, Chungsoo Orcid: 0000-0003-1802-1777 Kolde, Raivo Orcid: 0000-0003-2886-6298 Lee, Youngsoo Orcid: 0000-0001-8918-9353 Park, Hae-Sim Orcid: 0000-0003-2614-0303 Park, Rae Woong Orcid: 0000-0003-4989-3287 Prieto-Alhambra, Daniel Orcid: 0000-0002-3950-6346 Reyes, Carlen Orcid: 0000-0001-8486-3265 Krishnan, Jerry A Orcid: 0000-0001-5525-4778 Brusselle, Guy G Orcid: 0000-0001-7021-8505 Verhamme, Katia Mc Orcid: 0000-0001-8162-4904 Journal Article Research Support, Non-U.S. Gov't England 2024/02/28 BMJ Open Respir Res. 2024 Feb 27;11(1):e002127. doi: 10.1136/bmjresp-2023-002127.},
   abstract = {BACKGROUND: There is a lack of knowledge on how patients with asthma or chronic obstructive pulmonary disease (COPD) are globally treated in the real world, especially with regard to the initial pharmacological treatment of newly diagnosed patients and the different treatment trajectories. This knowledge is important to monitor and improve clinical practice. METHODS: This retrospective cohort study aims to characterise treatments using data from four claims (drug dispensing) and four electronic health record (EHR; drug prescriptions) databases across six countries and three continents, encompassing 1.3 million patients with asthma or COPD. We analysed treatment trajectories at drug class level from first diagnosis and visualised these in sunburst plots. RESULTS: In four countries (USA, UK, Spain and the Netherlands), most adults with asthma initiate treatment with short-acting ß2 agonists monotherapy (20.8%-47.4% of first-line treatments). For COPD, the most frequent first-line treatment varies by country. The largest percentages of untreated patients (for asthma and COPD) were found in claims databases (14.5%-33.2% for asthma and 27.0%-52.2% for COPD) from the USA as compared with EHR databases (6.9%-15.2% for asthma and 4.4%-17.5% for COPD) from European countries. The treatment trajectories showed step-up as well as step-down in treatments. CONCLUSION: Real-world data from claims and EHRs indicate that first-line treatments of asthma and COPD vary widely across countries. We found evidence of a stepwise approach in the pharmacological treatment of asthma and COPD, suggesting that treatments may be tailored to patients' needs.},
   keywords = {Adult
Humans
Retrospective Studies
Administration, Inhalation
Bronchodilator Agents/therapeutic use
Adrenergic beta-2 Receptor Agonists/therapeutic use
Adrenal Cortex Hormones/therapeutic use
*Pulmonary Disease, Chronic Obstructive/diagnosis/drug therapy/epidemiology
*Asthma/diagnosis/drug therapy/epidemiology
Asthma Pharmacology
COPD Pharmacology ,
ISSN = 2052-4439 ,
DOI = 10.1136/bmjresp-2023-002127},
   year = {2024},
   type = {Journal Article}
}

{"_id":"5A7BSQ9PXetJr2PWj","bibbaseid":"markus-rijnbeek-kors-burn-duartesalles-haug-kim-kolde-etal-realworldtreatmenttrajectoriesofadultswithnewlydiagnosedasthmaorcopd-2024","author_short":["Markus, A. F.","Rijnbeek, P. R.","Kors, J. A.","Burn, E.","Duarte-Salles, T.","Haug, M.","Kim, C.","Kolde, R.","Lee, Y.","Park, H. S.","Park, R. W.","Prieto-Alhambra, D.","Reyes, C.","Krishnan, J. A.","Brusselle, G. G.","Verhamme, K. M."],"bibdata":{"bibtype":"article","type":"Journal Article","author":[{"propositions":[],"lastnames":["Markus"],"firstnames":["A.","F."],"suffixes":[]},{"propositions":[],"lastnames":["Rijnbeek"],"firstnames":["P.","R."],"suffixes":[]},{"propositions":[],"lastnames":["Kors"],"firstnames":["J.","A."],"suffixes":[]},{"propositions":[],"lastnames":["Burn"],"firstnames":["E."],"suffixes":[]},{"propositions":[],"lastnames":["Duarte-Salles"],"firstnames":["T."],"suffixes":[]},{"propositions":[],"lastnames":["Haug"],"firstnames":["M."],"suffixes":[]},{"propositions":[],"lastnames":["Kim"],"firstnames":["C."],"suffixes":[]},{"propositions":[],"lastnames":["Kolde"],"firstnames":["R."],"suffixes":[]},{"propositions":[],"lastnames":["Lee"],"firstnames":["Y."],"suffixes":[]},{"propositions":[],"lastnames":["Park"],"firstnames":["H.","S."],"suffixes":[]},{"propositions":[],"lastnames":["Park"],"firstnames":["R.","W."],"suffixes":[]},{"propositions":[],"lastnames":["Prieto-Alhambra"],"firstnames":["D."],"suffixes":[]},{"propositions":[],"lastnames":["Reyes"],"firstnames":["C."],"suffixes":[]},{"propositions":[],"lastnames":["Krishnan"],"firstnames":["J.","A."],"suffixes":[]},{"propositions":[],"lastnames":["Brusselle"],"firstnames":["G.","G."],"suffixes":[]},{"propositions":[],"lastnames":["Verhamme"],"firstnames":["K.","M."],"suffixes":[]}],"title":"Real-world treatment trajectories of adults with newly diagnosed asthma or COPD","journal":"BMJ Open Respir Res","volume":"11","number":"1","note":"2052-4439 Markus, Aniek F Orcid: 0000-0001-5779-4794 Rijnbeek, Peter R Orcid: 0000-0003-0621-1979 Kors, Jan A Burn, Edward Orcid: 0000-0002-9286-1128 Duarte-Salles, Talita Orcid: 0000-0002-8274-0357 Haug, Markus Orcid: 0000-0003-0935-3307 Kim, Chungsoo Orcid: 0000-0003-1802-1777 Kolde, Raivo Orcid: 0000-0003-2886-6298 Lee, Youngsoo Orcid: 0000-0001-8918-9353 Park, Hae-Sim Orcid: 0000-0003-2614-0303 Park, Rae Woong Orcid: 0000-0003-4989-3287 Prieto-Alhambra, Daniel Orcid: 0000-0002-3950-6346 Reyes, Carlen Orcid: 0000-0001-8486-3265 Krishnan, Jerry A Orcid: 0000-0001-5525-4778 Brusselle, Guy G Orcid: 0000-0001-7021-8505 Verhamme, Katia Mc Orcid: 0000-0001-8162-4904 Journal Article Research Support, Non-U.S. Gov't England 2024/02/28 BMJ Open Respir Res. 2024 Feb 27;11(1):e002127. doi: 10.1136/bmjresp-2023-002127.","abstract":"BACKGROUND: There is a lack of knowledge on how patients with asthma or chronic obstructive pulmonary disease (COPD) are globally treated in the real world, especially with regard to the initial pharmacological treatment of newly diagnosed patients and the different treatment trajectories. This knowledge is important to monitor and improve clinical practice. METHODS: This retrospective cohort study aims to characterise treatments using data from four claims (drug dispensing) and four electronic health record (EHR; drug prescriptions) databases across six countries and three continents, encompassing 1.3 million patients with asthma or COPD. We analysed treatment trajectories at drug class level from first diagnosis and visualised these in sunburst plots. RESULTS: In four countries (USA, UK, Spain and the Netherlands), most adults with asthma initiate treatment with short-acting ß2 agonists monotherapy (20.8%-47.4% of first-line treatments). For COPD, the most frequent first-line treatment varies by country. The largest percentages of untreated patients (for asthma and COPD) were found in claims databases (14.5%-33.2% for asthma and 27.0%-52.2% for COPD) from the USA as compared with EHR databases (6.9%-15.2% for asthma and 4.4%-17.5% for COPD) from European countries. The treatment trajectories showed step-up as well as step-down in treatments. CONCLUSION: Real-world data from claims and EHRs indicate that first-line treatments of asthma and COPD vary widely across countries. We found evidence of a stepwise approach in the pharmacological treatment of asthma and COPD, suggesting that treatments may be tailored to patients' needs.","keywords":"Adult Humans Retrospective Studies Administration, Inhalation Bronchodilator Agents/therapeutic use Adrenergic beta-2 Receptor Agonists/therapeutic use Adrenal Cortex Hormones/therapeutic use *Pulmonary Disease, Chronic Obstructive/diagnosis/drug therapy/epidemiology *Asthma/diagnosis/drug therapy/epidemiology Asthma Pharmacology COPD Pharmacology , ISSN = 2052-4439 , DOI = 10.1136/bmjresp-2023-002127","year":"2024","bibtex":"@article{RN112,\r\n author = {Markus, A. F. and Rijnbeek, P. R. and Kors, J. A. and Burn, E. and Duarte-Salles, T. and Haug, M. and Kim, C. and Kolde, R. and Lee, Y. and Park, H. S. and Park, R. W. and Prieto-Alhambra, D. and Reyes, C. and Krishnan, J. A. and Brusselle, G. G. and Verhamme, K. M.},\r\n title = {Real-world treatment trajectories of adults with newly diagnosed asthma or COPD},\r\n journal = {BMJ Open Respir Res},\r\n volume = {11},\r\n number = {1},\r\n note = {2052-4439 Markus, Aniek F Orcid: 0000-0001-5779-4794 Rijnbeek, Peter R Orcid: 0000-0003-0621-1979 Kors, Jan A Burn, Edward Orcid: 0000-0002-9286-1128 Duarte-Salles, Talita Orcid: 0000-0002-8274-0357 Haug, Markus Orcid: 0000-0003-0935-3307 Kim, Chungsoo Orcid: 0000-0003-1802-1777 Kolde, Raivo Orcid: 0000-0003-2886-6298 Lee, Youngsoo Orcid: 0000-0001-8918-9353 Park, Hae-Sim Orcid: 0000-0003-2614-0303 Park, Rae Woong Orcid: 0000-0003-4989-3287 Prieto-Alhambra, Daniel Orcid: 0000-0002-3950-6346 Reyes, Carlen Orcid: 0000-0001-8486-3265 Krishnan, Jerry A Orcid: 0000-0001-5525-4778 Brusselle, Guy G Orcid: 0000-0001-7021-8505 Verhamme, Katia Mc Orcid: 0000-0001-8162-4904 Journal Article Research Support, Non-U.S. Gov't England 2024/02/28 BMJ Open Respir Res. 2024 Feb 27;11(1):e002127. doi: 10.1136/bmjresp-2023-002127.},\r\n abstract = {BACKGROUND: There is a lack of knowledge on how patients with asthma or chronic obstructive pulmonary disease (COPD) are globally treated in the real world, especially with regard to the initial pharmacological treatment of newly diagnosed patients and the different treatment trajectories. This knowledge is important to monitor and improve clinical practice. METHODS: This retrospective cohort study aims to characterise treatments using data from four claims (drug dispensing) and four electronic health record (EHR; drug prescriptions) databases across six countries and three continents, encompassing 1.3 million patients with asthma or COPD. We analysed treatment trajectories at drug class level from first diagnosis and visualised these in sunburst plots. RESULTS: In four countries (USA, UK, Spain and the Netherlands), most adults with asthma initiate treatment with short-acting ß2 agonists monotherapy (20.8%-47.4% of first-line treatments). For COPD, the most frequent first-line treatment varies by country. The largest percentages of untreated patients (for asthma and COPD) were found in claims databases (14.5%-33.2% for asthma and 27.0%-52.2% for COPD) from the USA as compared with EHR databases (6.9%-15.2% for asthma and 4.4%-17.5% for COPD) from European countries. The treatment trajectories showed step-up as well as step-down in treatments. CONCLUSION: Real-world data from claims and EHRs indicate that first-line treatments of asthma and COPD vary widely across countries. We found evidence of a stepwise approach in the pharmacological treatment of asthma and COPD, suggesting that treatments may be tailored to patients' needs.},\r\n keywords = {Adult\r\nHumans\r\nRetrospective Studies\r\nAdministration, Inhalation\r\nBronchodilator Agents/therapeutic use\r\nAdrenergic beta-2 Receptor Agonists/therapeutic use\r\nAdrenal Cortex Hormones/therapeutic use\r\n*Pulmonary Disease, Chronic Obstructive/diagnosis/drug therapy/epidemiology\r\n*Asthma/diagnosis/drug therapy/epidemiology\r\nAsthma Pharmacology\r\nCOPD Pharmacology ,\r\nISSN = 2052-4439 ,\r\nDOI = 10.1136/bmjresp-2023-002127},\r\n year = {2024},\r\n type = {Journal Article}\r\n}\r\n\r\n","author_short":["Markus, A. F.","Rijnbeek, P. R.","Kors, J. A.","Burn, E.","Duarte-Salles, T.","Haug, M.","Kim, C.","Kolde, R.","Lee, Y.","Park, H. S.","Park, R. W.","Prieto-Alhambra, D.","Reyes, C.","Krishnan, J. A.","Brusselle, G. G.","Verhamme, K. M."],"bibbaseid":"markus-rijnbeek-kors-burn-duartesalles-haug-kim-kolde-etal-realworldtreatmenttrajectoriesofadultswithnewlydiagnosedasthmaorcopd-2024","role":"author","urls":{},"keyword":["Adult Humans Retrospective Studies Administration","Inhalation Bronchodilator Agents/therapeutic use Adrenergic beta-2 Receptor Agonists/therapeutic use Adrenal Cortex Hormones/therapeutic use *Pulmonary Disease","Chronic Obstructive/diagnosis/drug therapy/epidemiology *Asthma/diagnosis/drug therapy/epidemiology Asthma Pharmacology COPD Pharmacology","ISSN = 2052-4439","DOI = 10.1136/bmjresp-2023-002127"],"metadata":{"authorlinks":{}}},"bibtype":"article","biburl":"https://bibbase.org/f/Y3pdXAEbo8qQHfE5w/IPCI Publications update 2025-2.bib","dataSources":["TB9sD3avjy7bNxfgS","vDmJPYmHEKAT3tMNL"],"keywords":["adult humans retrospective studies administration","inhalation bronchodilator agents/therapeutic use adrenergic beta-2 receptor agonists/therapeutic use adrenal cortex hormones/therapeutic use *pulmonary disease","chronic obstructive/diagnosis/drug therapy/epidemiology *asthma/diagnosis/drug therapy/epidemiology asthma pharmacology copd pharmacology","issn = 2052-4439","doi = 10.1136/bmjresp-2023-002127"],"search_terms":["real","world","treatment","trajectories","adults","newly","diagnosed","asthma","copd","markus","rijnbeek","kors","burn","duarte-salles","haug","kim","kolde","lee","park","park","prieto-alhambra","reyes","krishnan","brusselle","verhamme"],"title":"Real-world treatment trajectories of adults with newly diagnosed asthma or COPD","year":2024}